8 September 2022
Diurnal Group plc
("Diurnal" or the "Company")
Resignation of Joint Corporate Broker
Diurnal Group plc (AIM:DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that Stifel Nicolaus Europe Limited will cease to act as the Company's Joint Corporate Broker with immediate effect. As a result, the Company intends to have Panmure Gordon (UK) Limited continue as its Nominated Adviser and Sole Corporate Broker.
| For further information, please visit www.diurnal.co.uk or contact: | |
| | |
| Diurnal Group plc | +44 (0)20 3727 1000 |
| Richard Bungay, Interim Chief Executive Officer |
|
| |
|
| Panmure Gordon (UK) Limited (Nominated Adviser and Corporate Broker) | +44 (0)20 7886 2500 |
| Corporate Finance: Freddy Crossley, Emma Earl |
|
| Corporate Broking: Rupert Dearden
|
|
| FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
| Simon Conway | |
| Victoria Foster Mitchell | |
| Alex Davis | |
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.